In today’s episode, I am joined by Simon Arkell, the visionary CEO and co-founder of Ryght, to talk about copilots and the application of generative AI in life sciences. Ryght is dedicated to revolutionizing the field of life sciences through the power of AI. By leveraging cutting-edge technology and innovative solutions, Ryght aims to empower professionals and organizations within the life sciences industry to streamline processes, enhance productivity, and drive meaningful outcomes.
In our conversation, we discuss Simon's entrepreneurial background, the various companies he has founded, and what led him to create Ryght. We delve into the pivotal role of enterprise-scale, secure AI solutions in healthcare, and learn how Ryght's platform is reshaping the landscape of drug development and clinical research. Discover the intricate workings of generative AI copilots, the challenges of minimizing hallucinations and validating AI models, and why the utility of the approach at the enterprise level is essential. Simon also shares Ryght’s long-term goals and invaluable advice for leaders of AI startups. Join us, as we explore a world where healthcare and life sciences are transformed by cutting-edge technology with Simon Arkell from Ryght!
Key Points:
- Hear about Simon’s background and his path to founding Ryght.
- Ryght’s generative AI approach, its potential in life sciences, and the role of copilots.
- The importance of enterprise-scale, secure AI solutions in healthcare.
- How generative AI copilots accelerate drug development processes.
- Differences between training models for life sciences versus generic AI models.
- Discover the challenges encountered in AI-powered solutions.
- Explore the company’s approach to customer feedback and model validation.
- Strategic considerations and advice for leaders of AI startups.
- Ryght’s mission to transform the healthcare and life sciences industry.
- Where to find more information about Ryght and connect with Simon.
Quotes:
“We built an enterprise-secure version of Generative AI that has many different features that allow large companies and small companies to very securely benefit from Generative AI without all of the issues that a very insecure, non-industry-trained solution might create.” — Simon Arkell
“With this type of [generative AI] technology, you have the ability to completely unlock new formulas, and new molecules that could be life-changing.” — Simon Arkell
“Improving the utility of the platform comes down to the efficacy of the output. It comes down to the in-context learning, the ensembling, and the prompting. But at the end of the day, a human has to determine, in many cases, the accuracy and relevance of a specific answer.” — Simon Arkell
“It's not really about building models. It's about making sure that the right models are being utilized for the copilot.” — Simon Arkell